Sie sind nicht angemeldet! Dieses Tagebuch ist öffentlich einsehbar und wird demnächst zurückgesetzt.
 | |||||||
| |||||||
| © tratabu.de
© tratabu.de
|
Dividendenzahlungen |
|||
| Titel | Ex-Datum | Zahldatum | Bruttobetrag |
Sanofi SA |
12.05.25 |
14.05.25 |
3.9200 € |
Sanofi SA |
13.05.24 |
15.05.24 |
3.7600 € |
Sanofi SA |
30.05.23 |
01.06.23 |
3.5600 € |
Sanofi SA |
06.05.22 |
10.05.22 |
3.3300 € |
Sanofi SA |
05.05.21 |
07.05.21 |
3.1826 € |
Nachrichten |
||
| Datum / Uhrzeit | Titel | Bewertung |
| 14.07.25 10:04:00 | Europe Glucagon-like Peptide-1 (GLP-1) Agonists Research Report 2025 | Market to Reach $14.34 Billion by 2034, Driven by Innovative R&D, Strategic |  |
| Company Logo The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by rising diabetes and obesity rates, innovative drug formulations, and supportive healthcare policies, the market is expanding. Key players include Eli Lilly, Sanofi, and Novo Nordisk. Challenges involve high costs and regulatory complexities. Opportunities lie in obesity treatment expansion and advanced drug delivery systems. European Glucagon-like Peptide-1 (GLP-1) Agonists MarketEuropean Glucagon-like Peptide-1 (GLP-1) Agonists Market Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034" has been added to ResearchAndMarkets.com's offering. The Europe glucagon-like peptide-1 (GLP-1) agonists market is projected to witness significant growth, fueled primarily by an increased prevalence of type 2 diabetes and obesity. Originally valued at USD 7.09 billion in 2024, the market is estimated to expand at a compound annual growth rate (CAGR) of 17.30%, expecting a valuation of USD 14.34 billion by 2034. The competitive landscape features major pharmaceutical firms like Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and others focused on innovative R&D, strategic collaborations, and drug formulation advancements. These companies aim to enhance market presence through mergers, acquisitions, and partnerships that promote access and compliance, ensuring sustained growth in the Europe's GLP-1 agonists market. The market's expansion is propelled by the increasing incidence of diabetes and obesity, augmented by sedentary lifestyles and poor dietary choices. GLP-1 agonists, as incretin-based therapies, are preferred for their efficacy in controlling blood sugar levels and facilitating weight loss, crucial aspects in managing diabetes and obesity. The growth trajectory is supported by rising healthcare expenditure, a burgeoning elderly demographic, advancements in drug delivery, and a robust regulatory framework favoring novel therapeutic adoption. Key Attributes: Report Attribute Details No. of Pages 300 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $7.09 Billion Forecasted Market Value (USD) by 2034 $14.34 Billion Compound Annual Growth Rate 7.3% Regions Covered Europe Market Drivers A surge in type 2 diabetes and obesity cases. Favorable government initiatives and reimbursement policies bolstering access to innovative treatments. Improved drug formulations like once-weekly injectables and oral options enhancing patient compliance. A growing trend towards combination therapies integrating GLP-1 agonists for optimized results. Story Continues Market Challenges High costs of GLP-1 therapies affecting widespread accessibility. Potential side effects that could hinder patient adherence. Regulatory complexities delaying new therapy commercializations. Future Opportunities Expanding applications in obesity treatment beyond diabetes management. Innovative drug delivery system developments heightening market penetration. Strategic R&D investments for next-gen GLP-1 therapies with enhanced efficacy. Europe GLP-1 Agonists Market Trends The shift towards long-acting GLP-1 formulations like once-weekly injections elevating patient compliance. The increasing use of GLP-1 agonists in obesity management, supported by regulatory endorsements. Clinical validation of cardiovascular benefits driving GLP-1 adoption among patients at cardiovascular risk. Policymaker efforts in expanding healthcare coverage improving treatment accessibility. The development of multi-target GLP-1 therapies promises superior management of diabetes and weight issues. Strategic collaborations in biosimilar production broadening market access and affordability. Market Segmentation By Drugs: Key drugs include dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. By Application: The applications span type 2 diabetes mellitus and obesity treatment. By Route of Administration: Dominated by parenteral routes, the market is gradually seeing a rise in oral solution adoption. By End User: Primary users are hospitals, specialty clinics, academic research sites, with home care settings gaining traction. By Distribution Channel: Hospital pharmacies prevail, while retail and online pharmacies steadily gain ground. By Region: The United Kingdom, Germany, France, and Italy emerge as principal markets, bolstered by strong infrastructure and supportive policies. Companies Featured Eli Lilly and Company Sanofi Novo Nordisk A/S AstraZeneca plc For more information about this report visit https://www.researchandmarkets.com/r/a9i9v7 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Glucagon-like Peptide-1 (GLP-1) Agonists Market CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 View Comments |
||
| 10.07.25 04:39:45 | Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating |  |
| Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.Morgan Stanley analyst Judah Frommer assumed coverage of the company’s stock with an “Overweight” rating and a price objective of $70, down from $79. The research firm mentioned that the company is developing oral small-molecule approaches to target immunological pathways, which are validated by biologics. As per the firm’s analyst, healthy volunteer data with KT-621 demonstrates a potential multi-blockbuster opportunity.Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating A biopharmaceutical laboratory with scientists in lab coats working on medicines. Furthermore, the partnerships with Sanofi and Gilead tend to further validate Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s drug discovery and protein degradation capabilities, added the analyst. Sanofi informed the company that KT-485/SAR447971, which is an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases that Kymera Therapeutics, Inc. (NASDAQ:KYMR) discovered and characterized via preclinical studies, was selected to advance into the clinical studies. After the extensive preclinical work aiding strong development potential, KT-485 continues to be prioritized for development under the companies’ existing IRAK4 collaboration, and is projected to advance into Phase 1 testing next year. Kymera Therapeutics, Inc. (NASDAQ:KYMR) saw collaboration revenues of $22.1 million for Q1 2025 as compared to $10.3 million for Q1 2024. Furthermore, the collaboration revenues were all attributable to its Sanofi collaboration. While we acknowledge the potential of KYMR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. View Comments |
||
| 09.07.25 16:29:00 | Sanofi: Information concerning the total number of voting rights and shares - June 2025 | |
| Sanofi Winthrop Industrie Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofi a French société anonyme with a registered share capital of €2,452,461,656 Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris Commercial and Companies Registry under number 395 030 844 Date Total number of issued shares Number of real voting rights (excluding treasury shares) Theoretical number of voting rights (including treasury shares)* 30 June 2025 1,227,756,274 1,351,296,496 1,361,952,562 * Pursuant to Article 223-11 of the Règlement général de l’Autorité des Marchés Financiers. This information is also available on the internet website of sanofi under « Regulated Information in France »: https://www.sanofi.com/en/investors/sanofi-share-and-adrs/share-overview/shares-and-voting-rights/ Investor Relations Department e-mail: investor.relations@sanofi.com Attachment EN_number_of_voting_rights_and_shares_June_2025 View Comments |
||
| 08.07.25 19:31:00 | Regeneron’s Blockbuster Dupixent Faces a New Rival | |
| The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics. Continue Reading View Comments |
||
| 07.07.25 14:08:23 | Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker. | |
| Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot to control eczema. Continue Reading View Comments |
||
| 06.07.25 07:35:58 | FDA Grants Orphan Drug Designation To Sanofi’s (SNY) Riliprubart | |
| Sanofi (NASDAQ:SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) announced that the FDA granted orphan drug designation to Riliprubart for treating antibody-mediated rejection in solid organ transplantation. The FDA grants orphan drug designation to drugs aimed at treating rare diseases or conditions affecting fewer than 200,000 people in the US. This is a significant milestone for Sanofi (NASDAQ:SNY) as it provides benefits including tax credits, user fee waivers, and market exclusivity upon approval.FDA Grants Orphan Drug Designation To Sanofi's (SNY) Riliprubart Dozens of pharmaceutical capsules piled on top of one another to show the scale of the company's drug contributions to the industry. Riliprubart is currently being evaluated in multiple clinical trials across different indications, including transplant and neurology. The phase 2 study is underway to assess its efficacy in kidney transplant recipients. Sanofi (NASDAQ:SNY) is also conducting two phase 3 trials investigating Riliprubart in chronic inflammatory demyelinating polyneuropathy. Sanofi (NASDAQ:SNY) is a leading healthcare company headquartered in France. It focuses on improving patient health through the research, development, manufacturing, and marketing of a wide range of therapeutic solutions. While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. |
||
| 06.07.25 07:35:11 | Sanofi’s (NASDAQ:SNY) Riliprubart Granted Orphan Frug Designation in Japan | |
| Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now.On June 30, Sanofi (NASDAQ:SNY) announced that its Riliprubart has been granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy. Riliprubart is a monoclonal antibody that specifically inhibits activated C1s in the classical complement pathway. The treatment is designed to block a very specific part of the immune system’s response. Orphan drug designation is a special status granted by regulatory bodies for medicines that target rare diseases or conditions where there is a high unmet medical need.Sanofi's (NASDAQ:SNY) Riliprubart Granted Orphan Frug Designation in Japan Dozens of pharmaceutical capsules piled on top of one another to show the scale of the company's drug contributions to the industry. This is a significant achievement for Sanofi (NASDAQ:SNY) because, despite existing treatments, around 30% of patients do not respond adequately, leaving a significant unmet medical need. Sanofi (NASDAQ:SNY) presented 76-week long-term data from a phase 2 clinical trial at the Peripheral Nerve Society meeting in Edinburgh. The results suggest sustained efficacy and safety of Riliprubart in a broad range of CIDP patients. Management noted that two phase 3 studies are underway to further evaluate the treatment. While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. View Comments |
||
| 03.07.25 06:47:34 | Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA | |
| Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that the US FDA approved Dupixent® (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP). The approval for bullous pemphigoid brings a novel treatment approach to patients and their caregivers. Also, this approval extends the ability of Dupixent to transform treatment paradigms for people who live with a variety of diseases with underlying type 2 inflammation, from common conditions such as asthma and atopic dermatitis, to rarer ones, including eosinophilic esophagitis and prurigo nodularis, and now including bullous pemphigoid.Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality. Dupixent demonstrated the potential to improve the most challenging effects of bullous pemphigoid, while, at the same time, supporting some patients in achieving sustained disease remission as well as decreased oral corticosteroid use. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) highlighted that the approval also reinforced the demonstrated safety profile of Dupixent in a broad age range of patients, from infants to elderly people, and throughout dermatological, respiratory, and gastrointestinal diseases. The FDA approval was on the basis of data from the pivotal ADEPT Phase 2/3 trial, which evaluated the efficacy and safety of Dupixent as compared to placebo in adults with moderate-to-severe BP. While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. View Comments |
||
| 01.07.25 13:27:39 | Sector Update: Health Care Stocks Lean Lower Premarket Tuesday | |
| Health care stocks were leaning lower premarket Tuesday with the iShares Biotechnology ETF (IBB) and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in |
||
| 01.07.25 11:00:00 | Adagene announces up to $25 million strategic investment from Sanofi | |
| Adagene Inc. - Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - Company expects proceeds to extend cash runway into 2027 SAN DIEGO and SUZHOU, China, July 01, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced strategic investment and option exercise by Sanofi (Euronext: SAN FP). Sanofi has agreed to make strategic investment of up to US$25 million in Adagene. The Company plans to use the proceeds to fund its research and development activities, including clinical development of muzastotug (ADG126), an anti-CTLA-4 SAFEbody, through a randomized phase 2 trial in microsatellite stable colorectal cancer (MSS CRC). To further explore the clinical potential of muzastotug, Adagene will supply Sanofi with muzastotug to evaluate the safety, efficacy, pharmacokinetics and biomarker data in combination with other anticancer therapies in over 100 patients in a phase 1/2 clinical trial in advanced solid tumors. Adagene continues to own worldwide commercial rights to muzastotug. Sanofi has also exercised its option to select a third SAFEbody discovery program, utilizing Adagene’s proprietary masking technology and antibody engineering expertise. The bispecific therapeutic, with undisclosed targets, will be engineered by Adagene and induces an option exercise fee, as well as milestones and royalties as per the 2022 partnership agreement with Adagene. “Expanding our partnership with Sanofi highlights the potential of our SAFEbody platform and the clinical proof of concept for ADG126, our masked anti-CTLA-4 program and the most advanced of its kind,” said Peter Luo, Chairman, CEO and President of R&D at Adagene. “This strategic partnership reinforces our shared vision of ADG126’s promise in advanced solid tumors, including MSS CRC, where dose-limiting challenges have hindered anti-CTLA-4 therapies. We value our trusted relationship with Sanofi.” As of December 31, 2024, the Company had audited cash and cash equivalents of US$85.2 million. The proceeds from the investment of Sanofi, together with the current cash and cash equivalents, are expected to be sufficient to fund planned operations into 2027. Following the equity investment and strategic collaborations, a Sanofi representative will join Adagene’s Scientific Advisory Board (SAB), which provides strategic advice on the scientific and clinical aspects of the Company’s activities. Story Continues About Adagene Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues. Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers. For more information, please visit: https://investor.adagene.com. Follow Adagene on WeChat, LinkedIn and X. SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union. Safe Harbor Statement This press release contains forward-looking statements, including statements regarding the impact of Sanofi’s strategic investment and Adagene’s relationship with Sanofi; the expected timeframe for funding Adagene’s operating plan with current cash and cash equivalents and the proceeds from Sanofi’s investment; certain clinical results of ADG126, the potential implications of clinical data for patients, and Adagene’s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Investor Contacts: Raymond Tam raymond_tam@adagene.com Corey Davis LifeSci Advisors cdavis@lifesciadvisors.com Media Contact: Lindsay Rocco Elixir Health Public Relations lrocco@elixirhealthpr.com +1 862-596-1304 View Comments |
||
